Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Korea To Limit Olmutinib Usage, Monitor All Patients

Executive Summary

After distributing safety letters on several cases of serious adverse skin reactions that occurred during the clinical development of Hanmi’s olmutinib, South Korean authorities have decided to limit the EGFR inhibitor to consenting patients and are closely monitoring its use.


Related Content

Hanmi’s Case: One Failure Doesn’t Speak For All
Korea Plans Breakthrough System To Encourage Innovation
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors
Korean Authorities Mull New Steps, Probe Over Olmutinib Events
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair


Related Companies